Global Information
회사소개 | 문의 | 위시리스트

사람 유전자 시퀀싱 시장 분석과 예측(2020-2024년)

Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct To Consumer, by Country. With Executive and Consultant Guides. 2020 to 2024

리서치사 Howe Sound Research
발행일 2019년 11월 상품 코드 766998
페이지 정보 영문 489 Pages
가격
US $ 6,995 ₩ 8,245,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 12,371,000 PDF by E-mail (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 16,497,000 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



사람 유전자 시퀀싱 시장 분석과 예측(2020-2024년) Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct To Consumer, by Country. With Executive and Consultant Guides. 2020 to 2024
발행일 : 2019년 11월 페이지 정보 : 영문 489 Pages

세계의 사람 유전자 시퀀싱(Human Gene Sequencing) 시장을 조사했으며, 시장 및 기술 정의와 개요, 각종 참여 사업자와 역할, 사람 유전자 시퀀싱의 용도 및 도입 사례, 주요 기업 개요, 시장 성장 영향요인 분석, 기술 개발 및 사업 추진 등의 동향, 용도별 시장 성장 예측, 향후 전망 등의 정보를 정리하여 전해드립니다.

제1장 서론 및 시장 정의

제2장 시장 개요

  • 다양한 역할을 하는 각종 참여 사업자
  • 사람 유전자 시퀀싱 : 시장, 사례, 검토
  • 산업 구조

제3장 시장 동향

  • 성장 촉진요인
  • 성장 억제요인
  • 시퀀싱 기기

제4장 사람 유전자 시퀀싱 : 최근의 발전

  • Fluxion Bio : NIPT 어세이 개발을 위한 NIH 보조금 획득
  • Illumina와 Broad Institute : 게놈 분석 소프트웨어에서 협력
  • Illumina와 Adaptive Biotechnologies : 면역 시퀀싱을 위한 IVD 테스트 제휴
  • Menarini Silicon Biosystems와 BlueBee : 시퀀싱 데이터 분석 플랫폼에서 제휴
  • NIH : 100만명 규모의 시퀀싱으로 Color에 자금 제공
  • Veritas Genetics : 전체 게놈 시퀀싱 가격을 40% 인하
  • 중증 환자를 위한 초고속 유전자 시퀀싱 진단
  • 새로운 혈액검사에 의한 대장암 검출
  • PerkinElmer Genomics : 의사 오더에 의한 유전자 스크리닝 검사 도입
  • Roche : 암 검사를 위한 돌연변이 프로파일러 소프트웨어로 CE 마크를 획득
  • PGDx와 PathGroup : 공동 개발에 합의, 기타

제5장 주요 기업 개요

제6장 세계 시장 규모

  • 시장 규모 : 용도별

제7장 시장 규모 : 용도별

  • 유전성 유전자 시퀀싱
  • 신생아 유전자 시퀀싱
  • NIPT 유전자 시퀀싱
  • 암 유전자 시퀀싱
  • 약물유전체학적 유전자 시퀀싱
  • D2C 유전자 시퀀싱

제8장 향후의 비전

LSH 19.10.17

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • Table 3 Lab Spending 2014 to 2024
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Human Gene Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 The Factors Driving Growth
  • Table 9 Factors Limiting Growth
  • Table 10 - Listing of Current NGS Instrument Specifications
  • Table 11 Six New Sequencing Technologies
  • Table 12 Global Market by Application
  • Table 13 Hereditary Segment by Country
  • Table 14 Newborn Segment by Country
  • Table 15 NIPT Segment by Country
  • Table 16 Oncology Segment by Country
  • Table 17 Pharmacogenomic Segment by Country
  • Table 18 Direct To Consumer Segment by Country
  • Table 19 2019 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Clinical Lab Spending 2014 to 2024
  • Figure 2 Gene Sequencing
  • Figure 3 TruSight Germline Panel
  • Figure 4 Historical Cost of Gene Sequencing
  • Figure 5 - Cost To Sequence a Human Genome
  • Figure 6 Application Share by Year
  • Figure 7 Application Segment Growth Rates
  • Figure 8 Segment Share Shifts
  • Figure 9 Hereditary vs. Total Market Growth
  • Figure 10 Newborn vs. Total Market Growth
  • Figure 11 NIPT vs. Total Market Growth
  • Figure 12 Oncology vs. Total Market Growth
  • Figure 13 Pharmacogenomic vs. Total Market Growth
  • Figure 14 Direct To Consumer vs. Total Market Growth

OVERVIEW:

Will all newborns receive genetic testing at birth? Why has Direct to Consumer Testing taken a big jump? What's holding the industry back? Where are the over 800 locations that have high throughput sequencing devices?

Our facts and support = Your success.

The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Gene Sequencing Markets - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Gene Sequencing Definition In This Report
    • 1.1.1 Gene Sequencing
    • 1.1.2 Hereditary
    • 1.1.3 Newborn Screening
    • 1.1.4 Non Invasise Prenatal Testing
    • 1.1.5 Oncology
    • 1.1.6 Pharmacogenomic
    • 1.1.7 Direct to Consumer
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for laboratory testing
  • 1.5 Genetic Testing vs. Gene Sequencing
    • 1.5.1 Cost and Pricing Practice
  • 1A Global Listing of Sequencer Installed Base - Location & Contacts
    • 1A.1 Notes to Installed Base Listing

2. Market Overview

  • 2.1 Market Participants Play Different Roles
    • 2.1.1 Instrument Manufacturer
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Sequencing Labs
    • 2.1.10 Audit body
  • 2.2 Human Gene Sequencing -Markets, Examples and Discussion
    • 2.2.1 Inherited Disease - Not what it used to be
      • 2.2.1.1 Clinical and Research Lines Blur
      • 2.2.1.2 Genetic Counselling - Not so simple anymore
      • 2.2.1.3 The Genetic Blizzard - Issues of Access and Payment
    • 2.2.2 Newborn Screening - The Standard of Care
      • 2.2.2.1 Newborn Screening - Do Parents Want to Know?
    • 2.2.3 NIPT - We've Only Just Begun
      • 2.2.3.1 NIPT, IVF and the Fertility Practice - PGS, PGD, CCS
      • 2.2.3.2 NIPT in the Future - Beyond Inherited Disease
    • 2.2.4 Oncology - Understanding Two Worlds
      • 2.2.4.1 The Tumor - A Sequence of Sequencing
      • 2.2.4.2 The Tumor - Biopsy and Liquid Biopsy
      • 2.2.4.3 The Human Genome - Predisposition and Prognosis
    • 2.2.5 Pharmacogenomics
      • 2.2.5.1 Sequencing Not the Only Player
      • 2.2.5.2 New Roles for Old Drugs - A Research Bonanza?
    • 2.2.6 Direct To Consumer - More Than Meets the Eye
      • 2.2.6.1 DTC - How Many Segments?
  • 2.3 Industry Structure
    • 2.3.1 Hospital's Testing Share
    • 2.3.2 The Rise of the Sequencing Lab
    • 2.3.3 Sequencing as a Commodity
    • 2.3.4 Informatics
    • 2.3.5 Instrument Manufacturer Role
    • 2.3.6 Healthcare Industry Impacts - Still Struggling
    • 2.3.7 Can the Healthcare Industry Adapt?
    • 2.3.8 Genetic Counselling as an Industry
    • 2.3.9 Sequencing Adoption and Cannibalization

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 New Diagnoses
    • 3.1.2 Wellness and Prevention
    • 3.1.3 Fertility Technology
    • 3.1.4 Cancer - Screening, Management and Monitoring
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs
    • 3.2.3 Healthcare Cost Concerns Curtail Growth.
    • 3.2.4 Wellness has a downside
  • 3.3 Sequencing Instrumentation
    • 3.3.1 Instrumentation Tenacity.
    • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
    • 3.3.3 LISTING of CURRENT INSTRUMENT SPECIFICATIONS
    • 3.3.4 Long Reads - Further Segmentation
    • 3.3.5 Linked Reads
    • 3.3.6 New Sequencing Technologies

4. Human Gene Sequencing Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • Fluxion Bio Wins NIH Grant to Develop NIPT Assay
      • Illumina, Broad Institute Collaborate on Genome Analysis Software
      • Illumina, Adaptive Biotechnologies Partner on IVD Test Kits for Immune Sequencing
      • Menarini Silicon Biosystems, BlueBee Partner on Sequencing Data Analysis Platform
      • Paying cash for elective genomic sequencing
      • NIH funds Color ahead of million-person sequencing effort
      • Veritas Genetics slashes price of whole genome sequencing 40% to $600
      • Superfast gene sequencing diagnoses critically ill patients
      • New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
      • PerkinElmer Genomics Introduces Physician-Ordered Genetic Screening Test for Proactive
      • Health Management
      • Roche Gets CE Mark for Mutation Profiler Software for NGS Cancer Tests
      • PGDx and PathGroup Enter Co-Development Agreement
      • Newborn genomic sequencing detects unanticipated disease risk factors
      • llumina to Acquire Pacific Biosciences for $1.2 Billion

5. Profiles of Key Companies

  • 10x Genomics, Inc
  • 23andME Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Cepheid (now Danaher
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Color Genomics
  • Complete Genomics, Inc. - A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gene by Gene, Ltd.
  • Genedrive
  • GeneFirst Ltd
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd
  • Omega Bioservices
  • OncoDNA
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Veritas Genetics
  • Volition

6. Global Market Size

  • 6.1 Global Market by Application

7. Market Sizes by Application

  • 7.1 Hereditary Gene Sequencing Market
  • 7.2 Newborn Gene Sequencing Market
  • 7.3 NIPT Gene Sequencing Market
  • 7.4 Oncology Gene Sequencing Market
  • 7.5 Pharmacogenomic Gene Sequencing Market
  • 7.6 Direct To Consumer Gene Sequencing Market

8. Vision of the Future of Human Gene Sequencing

Appendices

  • I. United States Medicare System: 2019 laboratory Fees Schedule
  • II Methodology
  • II.1 Authors
  • II.2 Sources
Back to Top
전화 문의
F A Q